10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice
The article reviews studies evaluating the efficacy and safety of eribulin chemotherapy in patients with HER2-negative advanced breast cancer. It analyzes the results derived from large randomized studies, highlights the main advantages peculiar to eribulin, and describes the key mechanisms of the a...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
ABV-press,
2021-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|